Literature DB >> 10956414

Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients.

H Mueller1, N Flury, S Eppenberger-Castori, W Kueng, F David, U Eppenberger.   

Abstract

Signaling through pathways involving mitogen-activated protein kinases (MAP kinases) has been implicated in the pathogenesis of cancer. Thus, the activity of MAP kinase is essential in the malignant potential of human breast tumors. p42/44(MAPK) was significantly higher expressed in tumor samples than in matching normal tissues adjacent to the tumor. p42/44(MAPK) protein expression correlated with enhanced MAP kinase activity only in a subset of tumors, indicating that over-expression of MAP kinases does not reflect the activation status of these enzymes. MAP kinase activity was significantly elevated in 131 tissue samples from primary breast tumors when compared to 18 normal tissues adjacent to tumors. A trend for higher MAP kinase activity in primary tumors of node-positive patients was observed when compared with tumors from node-negative patients. Similarly, higher MAP kinase activities were observed in specimens from patients who had a relapse within the follow-up time of 40 months when compared with patients with no relapse. A survival analysis demonstrated that the MAP kinase activity in primary breast tumors is potentially prognostic for relapse-free survival of patients. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10956414     DOI: 10.1002/1097-0215(20000720)89:4<384::aid-ijc11>3.0.co;2-r

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  44 in total

1.  Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

Authors:  John J Tentler; Sujatha Nallapareddy; Aik Choon Tan; Anna Spreafico; Todd M Pitts; M Pia Morelli; Heather M Selby; Maria I Kachaeva; Sara A Flanigan; Gillian N Kulikowski; Stephen Leong; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Mol Cancer Ther       Date:  2010-10-05       Impact factor: 6.261

2.  The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.

Authors:  Sara Koenig McLaughlin; Sarah Naomi Olsen; Benjamin Dake; Thomas De Raedt; Elgene Lim; Roderick Terry Bronson; Rameen Beroukhim; Kornelia Polyak; Myles Brown; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

3.  Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.

Authors:  Jason P Wong; Timothy J Stuhlmiller; Louise C Giffin; Carolina Lin; Rachele Bigi; Jichen Zhao; Weihe Zhang; Ariana G Bravo Cruz; Steven I Park; H Shelton Earp; Dirk P Dittmer; Stephen V Frye; Xiaodong Wang; Gary L Johnson; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-25       Impact factor: 11.205

Review 4.  Emerging targeted agents in metastatic breast cancer.

Authors:  Dimitrios Zardavas; José Baselga; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2013-03-05       Impact factor: 66.675

5.  MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.

Authors:  Chandra Bartholomeusz; Xuemei Xie; Mary Kathryn Pitner; Kimie Kondo; Ali Dadbin; Jangsoon Lee; Hitomi Saso; Paul D Smith; Kevin N Dalby; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2015-09-17       Impact factor: 6.261

6.  ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.

Authors:  Sheng-Li Lin; Li-Ying Yan; Xin-Tian Zhang; Ju Yuan; Mo Li; Jie Qiao; Zhao-Yi Wang; Qing-Yuan Sun
Journal:  PLoS One       Date:  2010-02-02       Impact factor: 3.240

7.  Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.

Authors:  Mehmet Salih Iyikesici; Gul Basaran; Faysal Dane; Meltem Ekenel; P Fulden Yumuk; Devrim Cabuk; Mehmet Teomete; N Serdar Turhal
Journal:  Int J Clin Exp Med       Date:  2014-05-15

8.  Diet and lifestyle factors interact with MAPK genes to influence survival: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Lisa H Hines; Abbie Lundgreen; Kathy B Baumgartner; Roger K Wolff; Mariana C Stern; Esther M John
Journal:  Cancer Causes Control       Date:  2014-07-04       Impact factor: 2.506

9.  Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression.

Authors:  Haoming Chen; Genfeng Zhu; Yong Li; Ravi N Padia; Zheng Dong; Zhixing K Pan; Kebin Liu; Shuang Huang
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 10.  Key signalling nodes in mammary gland development and cancer. Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development.

Authors:  Jacqueline Whyte; Orla Bergin; Alessandro Bianchi; Sara McNally; Finian Martin
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.